Gradalis’ Vigil therapy dramatically extends survival in advanced ovarian cancer

The randomized, double-blind, placebo-controlled Phase 2b VITAL trial enrolled 91 patients with newly diagnosed Stage IIIb–IV epithelial ovarian cancer

AVEO Oncology doses first patient in pioneering AML clinical trial

The trial aims to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the combination therapy

Bayer acquires Attralus’ cardiac amyloidosis imaging agents

The deal to acquire AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) underscores Bayer’s commitment to expanding in molecular imaging and advancing precision cardiology

Lantern Pharma launches AI Center of Excellence in Bengaluru to scale precision drug discovery globally

CARsgen and Dispatch Bio launch groundbreaking CAR T collaboration in China

CARsgen is working to transform outcomes for patients with solid tumors by advancing the potential of CAR T technologies

Thermo Fisher and NVIDIA team up to supercharge labs with AI

Artificial intelligence coupled with laboratory automation will transform how scientific work is performed

ISVIR 2026 showcases cutting-edge interventional radiology in India

Sabitha highlighted the growing relevance of minimally invasive therapies in modern medicine

Pierre Fabre and Iktos team up to accelerate AI-driven cancer drug discovery

Iktos will deploy its AI-driven tools to accelerate the identification of optimized small-molecule candidates against a currently undisclosed oncology target

GRIN Therapeutics launches global Phase 3 trial for groundbreaking GRIN-NDD therapy

GRIN-NDD is one of the most complex neurodevelopmental disorders with limited treatment options today

Bayer acquires Attralus’ cutting-edge cardiac amyloidosis imaging agents

The acquisition of AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) positions Bayer at the forefront of cardiac amyloidosis diagnostics